6
X
HCM increases the risk for comorbidities and mortality1-3
Serious complications of hypertrophic cardiomyopathy (HCM) may include atrial fibrillation (AFib), stroke, heart failure and mortality1-3
An investigation of a community-based population of 480 patients with HCM found that4:
Patients with HCM were up to
more likely to
develop AFib
Ischemic strokes were
8
X
more frequent in
these patients
with AFib
22
%
- 43
%
of patients with HCM
developed heart failure5,6
3
X
higher risk of mortality in older patients (aged 50 to 69 years) with HCM vs. the general population5
4
X
higher risk of mortality in younger patients (aged 20 to 29 years) with HCM vs. the general population5
HCM is the leading cause of sudden cardiac death (~1%) in younger patients1-3
HCM increases the risk of certain comorbidities as well as
mortality in patients of all ages1-3
References
- Ommen SR, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;142(25):e558-e631.
- Naidu, Srihari S, editor. Hypertrophic Cardiomyopathy. Second ed., Springer International Publishing, 2019.
- Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2011;142(6):e153-203.
- Olivotto I, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104(21):2517-24.
- Ho CY, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE). Circulation 2018;138(14):1387-98.
- Rowin EJ, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. Am J Cardiol 2017;120(12):2256-64.